Media Reports

2020.09.04

2020.9-Endpoints: AbbVie jumps into CD47 game, engineers $3B deal with ambitious Chinese player

Read at Endpoints

2020.09.04

2020.9-Scrip: $2bn AbbVie Deal Puts I-Mab On Global Immuno-Oncology Map

Read at Scrip

2020.05.25

Pharma Boardroom, May 25, 2020: Interview with I-Mab’s CEO Joan Shen

Read at Pharma Boardroom

2020.05.04

Genetic Engineering & Biotechnology News (GEN), May 4, 2020: Returning to Work: Biotech Companies in China Rev up to Supply Critical Products Amid COVID-19 Pandemic

Read at Genetic Engineering & Biotechnology News (GEN)

2020.04.23

Pharma Boardroom, April 23, 2020: Interview with I-Mab’s CFO Jielun Zhu

Read at Pharma Boardroom

2020.04.13

Biospectrum Asia, April 2020: Interview with I-Mab’s CFO Jielun Zhu

Read at Biospectrum Asia

2020.01.18

2020.1-Biocentury: I-Mab dips in NASDAQ debut, first in years for an innovative Chinese biopharma

Read at Biocentury

2020.01.17

2020.1-Endpoints: First Chinese biotech on Nasdaq in two years draws $104M

Read at Endpoints

2019.08.14

PHARMA Boardroom August 14, 2019: Interview with I-Mab’s President and CFO

Read at PHARMA Boardroom

2019.07.19

BioWorld July 19, 2019: CD47 race heats up in China as I-Mab’s antibody cleared for trials in advanced tumors

Read at BioWorld